ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CMPS COMPASS Pathways PLC

8.48
-1.02 (-10.74%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,563,752
Bid Price 8.77
Ask Price 8.95
News (1)
Company Name Stock Ticker Symbol Market Type
COMPASS Pathways PLC CMPS NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-1.02 -10.74% 8.48 19:56:13
Open Price Low Price High Price Close Price Prev Close
9.33 8.12 9.35 8.32 9.50
Trades Volume VWAP Dollar Volume Avg Volume
26,201 3,563,752  8.53  30,400,794 -
Last Trade Time Type Quantity Stock Price Currency
19:59:22 2  8.77 USD

COMPASS Pathways PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 0.00 - 4.06M -91.51M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News COMPASS Pathways

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CMPS Message Board. Create One! See More Posts on CMPS Message Board See More Message Board Posts

CMPS Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Your Recent History

Delayed Upgrade Clock